This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Cyclooxygenase-2 expression is dependent upon epidermal
growth factor receptor expression or activation in androgen
independent prostate cancer
Rui-Peng Jia1, Lu-Wei Xu1, Qi
Su1, Jian-Hua Zhao2, Wen-Cheng
Li1, Feng Wang3, Zheng
Xu1
Department of Urology,
2Department of Pathology, 3Center Laboratory, Nanjing First Hospital Affiliated to Nanjing
Medical University, Nanjing 210006, China
Abstract
Aim: To investigate the expression of cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) and
the possible mechanism in the development in androgen independent prostate cancer (AIPC).
Methods: Immunohistochemistry was performed on paraffin-embedded sections with goat polyclonal against COX-2 and mouse
monoclonal antibody against EGFR in 30 AIPC and 18 androgen dependent prostate cancer (ADPC) specimens. The effect
of epidermal growth factor (EGF) treatments on the expression of COX-2 and signal pathway in PC-3 and DU-145
cells was studied using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. ELISA
was used to measure prostaglandin E2 (PGE2) levels in the media of PC-3 and DU-145 incubated with EGF for 24 h.
Results: COX-2 was positively expressed in AIPC and ADPC, which were predominantly in endochylema of prostate
cancer (PCa) cells. Intense staining was seen in AIPC (80%) and in ADPC (55.5%), but there was no significant
association between the two groups. EGFR expression was also positive in the two groups (61.8% in ADPC and 90%
in AIPC, P < 0.01). A significant association was found between
EGFR expression and a higher Gleason score
(P < 0.05) or tumor stage (P < 0.05). The expression of PGE2 was increased in PC-3 and DU-145 cells after being incubated
with EGF. Both p38MAPK and PI-3K pathway were involved in the PC-3 cell COX-2 upregulation course. In
DU-145, only p38MAPK pathway was associated with COX-2 upregulation.
Conclusion: EGFR activation induces COX-2 expression through PI-3K and/or p38MAPK pathways. COX-2 and EGFR inhibitors might have a cooperative
anti-tumor effect in PCa. (Asian J Androl 2008 Sep; 10:
758_764)
Keywords: cyclooxygenase 2; epidermal growth factor receptor; prostatic neoplasms
Correspondence to: Dr Lu-Wei Xu, Department of Urology, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing
210006, China.
Tel: +86-25-5227-1061 Fax: +86-25-5227-1060
E-mail: xuluwei1980@126.com
Received 2008-01-30 Accepted 2008-05-19
DOI: 10.1111/j.1745-7262.2008.00423.x
1 Introduction
Cyclooxygenase-2 (COX-2) is an inducible enzyme
stimulated by cytokines, growth factors, oncogenes, or
tumor promoters during inflammation or malignancy.
COX-2 expression is increased in association with
decreased apoptosis, increased tumor invasiveness,
immunosuppression and angiogenesis. Furthermore, increased
COX-2 expression correlates with poor differentiation,
increased tumor size, increased nodal and distant disease,
and decreased overall survival in a variety of cancers
[1_4]. In addition, there
is evidence that prostaglandin
E2(PGE2), a downstream product of COX-2 metabolism,
can phosphorlyate epidermal growth factor receptor
(EGFR) and trigger mitogenic signaling pathways in many
cancer cell lines [5, 6]. Selective EGFR inhibitors and
COX-2 inhibitors have been shown to have a
co-operative antitumour effect against cancer xenografts in nude
mice [7].
Epidemiological studies have shown that prolonged
aspirin ingestion reduces the incidence of prostate
cancer (PCa). This effect might result from, at least in part,
COX-2 inhibition [8, 9]. Many other studies have shown
over-expression of COX-2 in PCa and COX-2 over-expression has a good relationship with the development of
androgen independent prostate cancer (AIPC) [10_13],
but COX-2 level changes and regulation pattern in AIPC
is unresolved. The relationship between COX-2 and
EGFR is poorly understood in the pathogenesis of AIPC
now. We therefore sought to determine the expression
of COX-2 and EGFR in a series of surgically resected
PCa specimens and two AIPC cell lines to examine the
associations between these two factors and their impact
on prognosis.
2 Materials and methods
2.1 Tissue specimens
All PCa tissues included in the present study were
from 48 adenocarcinoma of prostate cases that were
diagnosed by two pathologists between 1999 and 2003.
The median age of the patients was 67 years (range from
58 years to 83 years). History, transrectal ultrasound,
computed tomography, magnetic resonance imaging and
isotope scanning of the skeleton were combined to
decide the clinical staging. These samples were obtained
from 18 patients whose clinical tumor staging was T1 or
T2 and who had received radical prostatectomies, and
from needle-biopsies of the remaining 30 patients. The
patients who had not been able to undertake radical
prostatectomies had received neoadjuvant complete
androgen ablation therapy based on luteinizing
hormone-releasing hormone agonist and an antiandrogen treatment
for 18_30 months (average 21.8 months), and had
presented with continued rises in prostate specific antigen
(PSA) levels or bone metastases. All patients were
followed up after therapy: 14 patients who accepted radical
prostatectomy did not have metastases and maintained
very low PSA levels (below 0.2 ng/mL), with no relapse;
and 4 patients who had had a radical prostatectomy had
biochemical recurrences (average PSA level 1.9 ng/mL).
Antiandrogen therapy was given intermittently to these 4
patients for a short period. We considered these 18 cases
to be androgen dependent prostate cancer (ADPC). The
other 30 patients presented with rises in PSA levels or
bone metastases. These 30 patients were determined to
have advanced hormone-refractory PCa. The PSA levels
of 14 patients before treatment were ¡Ü 10 ng/L, and the
others were > 10 ng/L. The Gleason scores of 16
patients were ¡Ü 7, and 32 patients' Gleason scores were
> 7. The study was conducted with the approval of the
ethical committee of Nanjing Medical University (Nanjing,
China).
2.2 Immunohistochemistry
COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and EGFR (R&D Company, Minneapolis, MIN, USA) expression were analyzed in paraffin embedded
tumor specimens from 48 patients. Sections (4 μm)
were incubated overnight at 4ºC with the following
antibodies (100:l per slide): COX-2: goat polyclonal IgG
(1:100 dilution) and EGFR mouse monoclonal antibody
(1:200 dilution). Following a phosphate buffered saline
(PBS) wash, secondary antibody was applied (COX-2:
biotinylated bovine anti-goat IgG/B [Santa Cruz] at a
dilution of 1:400 in PBS with 0.1% bovine serum albumin;
EGFR:biotinylated rabbit anti-mouse whole
immunoglobulins at a dilution of 1:400) and slides incubated for 30
min (room temperature, RT) prior to a PBS wash.
Avidin-biotin complex (ABC) solution (100:l) was applied to
each slide (incubated for 30 min RT). Slides were
mounted with a xylene-based mounting medium.
2.3 Specimen interpretation
Immunostained tissue sections were scored
according to the percentage of tumor cells positive for COX-2
or EGFR. The median number of positive tumor cells
stained was chosen as the cut-off point. The median
number of tumor cells staining positive for COX-2 was
10% and for EGFR the median value was 10%. All slides
were double interpreted at low power by individuals
blinded to survival data. Where differences were recorded, consensus was achieved using a dual-headed
microscope. All slides were examined by trained
pathologists in Nanjing First Hospital Affiliated to Nanjing
Medical University (Nanjing, China).
2.4 Cell culture
PC-3 and DU-145 cell lines (American Type Culture
Collection, Rockville, MD, USA) were routinely cultured
in RPMI 1640-maintained media containing 10% fetal
calf serum, 25 U/mL penicillin and 25 μg/mL streptomycin. In certain experiments, cells were treated
with epideramal growth factor (EGF), the MAPK
inhibitor SC203580, or phosphatidylinosito-3 kinase inhibitor
LY294002 (BioSource, Camarillo, CA, USA). All experiments were repeated at least three times.
2.5 Reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA from PC-3 and DU-145 cells was extracted using TRIzol (Gibco, Gaithersburg, MD, USA).
RT-PCR testing was performed using an RT-PCR system according to the manufacturer's instructions (Takara,
Shiga, Japan). The primers were as follows: up
5'-CGAGGTGTATGTATGAGTG TG-3' and down 5'-TCTAGCCAGAGTTTCACCGTA-3', and the length of
the production was 582 bp. Thirty-five cycles of
amplification were performed under the following conditions:
melting at 95ºC; annealing at 56ºC; and extension at 72ºC.
The PCR products were analyzed by electrophoresis on
a 2% agarose gel.
2.6 Western blotting
Total cell lysates were obtained from the PC-3 and
DU-145. The cell lines were stimulated with EGF
(10 μg/L) for 24 h in serum unsupplemented conditions. Equal
amounts (35 μg) of protein were resolved by 5% and
10% SDS-PAGE and transferred onto nitrocellulose
membranes (Amersham Biosciences, Uppsala, Sweden),
which were incubated with the appropriate goat polyclonal
COX-2 antibodies (Santa Cruz Biotechnology) with
1:100 dilution followed by incubation with
peroxidase-conjugated secondary antibodies [10]. The level of
β-actin expression was used as the internal control for equal
loading. The bands were compared by densitometry of
western blots using an Eastman Kodak Image Station
440CF (Kodak, New Haven, CT, USA), and the data were analyzed using Kodak ID V.3.5.4 (Scientific
Imaging System, Rockville, MD, USA).
2.7 ELISA
PC-3 and DU-145 cells were cultured in serum-free
medium incubated with 10 μg/L EGF, EGF and LY294002, EGF and SC203580, respectively. The
standard was prepared by obtaining 1.5 mL microfuge tubes.
The ELISA plate (Cayman Chemical, Ann Arbor, MI, USA), coated with goat antimouse IgG was loaded at 50
μL per well of standard. The plate was covered and placed
in 4ºC for 16 h. After the incubation period, all the liquid
from the wells were removed and the plate was washed
with wash buffer (Cayman Chemical) five times. Next,
200 μL of Ellman's reagent (Cayman Chemical) was added
to each well and the plate was covered and allowed to
develop in the dark with low shaking at room
temperature for 90 min. Following the developing step,
absorbance in each well at 405 nmol/L was read using a
microplate spectrophotometer (BMG Labtech FLUOStar
Optima, Offenburg, Germany). Wells containing Ellman's
reagent alone served as the blank for absorbance background.
2.8 Statistical analysis
Pearson's χ2-test was used to analyze the
relationship between COX-2 and EGFR, and associations with
clinical-pathological features. The Kaplan-Meier method was
used to generate survival plots and the log rank test was
used to assess statistical significance. P
< 0.05 was considered significant.
3 Results
3.1 COX-2 immunostaining
The cinnamomeous staining mean was positive. In
our study, intense staining was seen in AIPC (80%) and
in ADPC (55.5%), which were predominantly in endochylema of PCa cells. There was no significant
difference between them (P = 0.07) (Figure 1). COX-2
was also seen in benign prostatic hyperplasia (BPH) (30%).
A significant association was observed between COX-2
expression and higher Gleason scores (P < 0.05) and
tumor stage (P < 0.05).
3.2 EGFR immunostaining
Eleven ADPC were positive for EGFR expression (61.1%). EGFR expression was increased to 27 of 30
(90%) samples in AIPC patients. This difference was
statistically significant between the two groups
(P < 0.01). A significant association was observed between EGFR
expression and a higher Gleason score (P < 0.05) and between
EGFR expression and tumor stage (P < 0.05) (Figure 1).
3.3 Relationship between EGFR and COX-2 expression
and clinicopathological parameters in AIPC and ADPC
EGFR and COX-2 positive coexpression was found in 22 AIPC (73.3%), and only in 6 (33.3%) ADPC, and
no in BPH. The positive rate in AIPC was significantly
higher than that in ADPC and BPH; there was obvious
correlation only in AIPC (r = 0.5528,
P < 0.001). The 20 of 22 AIPC with coexperssion developed metastatic and
had an obviously poor prognosis (P < 0.05) (Table 1).
3.4 Effect of EGF stimulation on COX-2 levels signal
pathway in PC-3 and DU-145 cells in serum free
conditions
We analyzed in PC-3 and DU-145 cells the expression of COX-2 using RT-PCR and Western blot analysis.
RT-PCR analysis revealed that COX-2 is obviously upregulated after EGF stimulation in a dose-dependent
manner. Western blot analysis revealed that PC-3 and
DU-145 cells was the same. One of the major targets
for the therapy in PCa is EGFR that signals via the
phosphoinositide-3 kinase/Akt and MAPK pathways. In
this study we found that both p38MAPK and PI-3K
pathways were involved in the PC-3 cells COX-2 upregulation
course. Only p38MAPK pathway was associated with COX-2 upregulation in DU-145 (Figures 2 and 3).
3.5 ELISA
PGE2 was significantly increased after 10 mg/L EGF
stimulation in both PC-3 and DU-145 cell lines
(P < 0.05). In PC-3 cell lines, both LY294002 and SC203580 reduced
the production of PGE2 by EGF (P < 0.05); but PGE2
was only affected by SC203580 in DU-145 (Figure 4).
4 Discussion
PCa remains the most common cause of death among
urologic malignances. The majority of PCa patients will
develop AIDC after the initiation of androgen deprivation.
Many of the biologic events leading to a predominantly
hormone-independent state remain undefined up to now.
There is no effective therapy for this disease today.
Therefore, identification of new effective biology-based
therapy is important. Epidemiological and clinical
studies have found that COX-2 enzymes play a key role in
the progression of PCa. Recently, much attention has
been focused on the identification of COX-2 pathways
involved in ADPC to AIPC to characterize potential
therapeutic targets in cancer prevention and treatment [14,
15]. In our study, no difference was found in COX-2
expression between ADPC and AIPC, although COX-2
expression in PCa was significantly higher than in BPH.
COX-2 expression in PCa was associated with recurrence and metastatic. A significant association was also
observed between COX-2 expression and higher Gleason
scores (P < 0.05), and between COX-2 expression and
tumor stage.
Two EGFR family members, Erb-B1 and Her2 (Erb-B2), are frequently overexpressed in PCa, which is
associated with a more aggressive clinical outcome. The
expression of EGFR increases during the natural history
of PCa and is correlated with disease progression and
hormone-refractory disease [16]. In addition,
EGFR/Her2 and their ligands, EGF, play a critical role during
tumourigenesis of the prostate gland and EGFR
signaling has been linked to the progression of
androgen-dependent responsive PCa to androgen-independent [17,
19]. Elevated expression of both EGFR and its ligands
have been described in prostate tumors and in vitro
studies have indicated that the growth of the
androgen-independent prostate tumor cell line DU145 is regulated by
the autocrine activation of the EGFR by EGF [16, 19].
This indicates that EGFR activation is associated with
the development from ADPC to AIPC. In our study, we
found that EGFR levels are overexpressed in AIPC and
ADPC. A significant difference was found between them.
This indicates that EGFR might be associated with AIPC
development.
Despite in vitro data suggesting that COX-2
regulation is mediated, at least in part by EGFR signaling
pathways, the evidence for such an association is not
consistent in human tumors in vivo. Some studies have
demonstrated that there is association between EGFR
and COX-2 in hepatocellular and nasopharyngeal
carcinoma cases [20, 21], and others have found coexpression
of COX-2 and EGFR to be independently poor prognostic factors. However, no strong correlation has
previously been found between COX-2 and EGFR
immunopositivity [22, 23]. In our study, we used an
immunohistochemical analysis to find an obvious association
between EGFR and COX-2 in AIPC, but it did not exist in
ADPC. EGFR and COX-2 staining were dependent on each other in AIPC, but not in ADPC. We also found
that COX-2 levels were upregulated by EGF stimulation
in AIPC cell lines (PC-3, DU-145). To the best of our
knowledge, this is the first study to examine the
relationship between COX-2 and EGFR in respect to the
histological progression in ADPC and AIPC. Therefore, we
thought that the regulation between EGFR and COX-2
might be involved in the development from ADPC to AIPC.
In numerous cell types, EGFR activation results in
COX-2 expression. Our experiments determined the
signal transduction pathways used by activated EGFR to
rapidly induce COX-2 in PC-3 and DU-145 cells. EGFR
activation can cause receptor autophosphorylation, which
may trigger both PI3K-Akt and Ras-ERK signaling pathways, resulting in induction of COX-2 [24, 25]. In
our study, EGF upregulated COX-2 in both PC-3 and DU-145 cells in a dose-dependent manner. P38MAPK
pathway was involved in PC-3 and DU-145 cells COX-2
regulation, while PI-3K was only associated with PC-3
cell COX-2 regulation. PTEN expression was high in
DU-145, while PTEN encodes a lipid phospyhatase that
is a negative regulator of the phosphoinositide 30-kinase
pathway: this might lead to inactivation of PI-3K in
DU-145 cell, so LY294002 cannot block the COX-2
upregulation.
In summary, our study demonstrated that COX-2 and EGFR are overexpressed in PCa. There is obviously
correlation between these two factors in either tumor
samples or cell lines. EGFR activation induces COX-2
expression through PI-3K and/or p38MAPK signal
transduction pathways. Thus both COX-2 and EGFR
inhibitors might have a cooperative anti-tumor effect in PCa,
the availability of agents able to specifically interfere with
COX-2 and EGFR tyrosine kinase is of potential interest,
and might lead to effective treatment in the future.
Acknowledgment
This study was supported by Jiangsu Province Key
Laboratory of Human Functional Genomics (HFG007).
We would thank Zi-zheng Wang (Center Laboratory, Nanjing First Hospital Affiliated to Nanjing Medical
University, Nanjing, China) for technical assistance.
References
1 Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling
TE, Dannenberg AJ, et al. Regulation of cyclooxygenase-2 by
interferon gammaand transforming growth factor alpha in
normal human epidermal keratinocytes and squamous carcinoma cells: role of mitogen-activated protein kinases. J
Biol Chem 1999; 274: 29138_48.
2 Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann
HP. Inhibition of cyclooxygenase-2 activity by celecoxib does
not lead to radiosensitization of human prostate cancer cells in
vitro. Radiother Oncol 2007; 82: 229_38.
3 Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL,
et al. Synergistic induction of cyclooxygenase-2 by transforming
growth factor-beta1 and epidermal growth factor inhibits
apoptosis in epithelial cells. Neoplasia 1999; 1: 508_17.
4 Neeraja S, Ramakrishna B, Sreenath AS, Reddy GV, Reddy
PR, Reddanna P. Novel functional association of rat testicular
membrane-associated cytosolic glutathione S transferases and
cyclooxygenase in vitro. Asian J Androl 2005; 7: 171_8.
5 Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T,
Yoshimoto T. Growth stimulation and induction of epidermal
growth factor receptor by overpression of cyclooxygenase 1
and 2 in human colon carcinoma cells. Biochim Biophys Acta
1999; 1438: 120_30.
6 Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski
AS. Prostaglandin E2 transactivates EGF receptor: a novel
mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289_93.
7 Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS,
et al. Tumor growth inhibition by simultaneously blocking
epidermal growth factor receptor and cyclooxygenase-2 in a
xenograft model. Clin Cancer Res 2005; 11: 6261_9.
8 Lin DW, Nelson PS. The role of cyclooxygenase-2 inhibition
for the prevention and treatment of prostate carcinoma. Clin
Prostate Cancer 2003; 2: 119_26.
9 Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs
and cyclooxygenase-2 selective inhibitors for prostate cancer
chemoprevention. J Urol 2004; 171: S59-62.
10 Sooriakumaran P, Langley SE, Laing RW, Coley HM.
COX-2 inhibition: a possible role in the management of prostate
cancer? J Chemother 2007; 19: 21_32.
11 Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its
inhibition in cancer: is there a role? Drugs 2007; 67: 821_45.
12 Rao DS, Gui D, Koski ME, Popoviciu LM, Wang H, Reiter
RE, et al. An inverse relation between COX-2 and E-cadherin
expression correlates with aggressive histologic features in
prostate cancer. Appl Immunohistochem Mol Morphol 2006;
14: 375_83.
13 Narayanan BA, Narayanan NK, Davis L, Nargi D. RNA
interference-mediated cyclooxygenase-2 inhibition prevents
prostate cancer cell growth and induces differentiation:
modulation of neuronal protein synaptophysin, cyclin D1,
and androgen receptor. Mol Cancer Ther 2006; 5: 1117_25.
14 Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T,
Namiki M, et al. Cyclooxygenase-2 promotes prostate cancer
progression. Prostate 2002; 53: 232_40.
15 Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a
potential target in the prevention and treatment of
genitourinary tumors: a review. J Urol 2003; 169: 2352_9.
16 Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano
S, Autorino R, et al. Expression of epidermal growth factor
receptor correlates with disease relapse and progression to
androgen - independence in human prostate cancer. Clin Cancer
Res 2002; 8: 3438_44.
17 Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE,
Wikstrand CJ, et al. Combination therapy of inhibitors of
epidermal growth factor receptor/vascular endothelial growth
factor receptor 2 (AEE788) and the mammalian target of
rapamycin (RAD001) offers improved glioblastoma tumor
growth inhibition. Mol Cancer Ther 2005; 4: 101_12.
18 Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ,
Bosenberg MW, et al. Deregulated Akt3 activity promotes
development of malignant melanoma. Cancer Research 2004;
64: 7002_10.
19 Connolly JM, Rose DP. Autocrine regulation of DU145 human
prostate cancer cell growth by epidermal growth factor-related
polypeptides. Prostate 1991; 19: 173_80.
20 Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor
EP1 transactivates EGFR /MET receptor tyrosine kinases
and enhances invasiveness in human hepatocellular carcinoma
cells. J Cell Physiol 2006; 207: 261_70.
21 Soo R, Putti T, Tao Q, Goh BC, Lee KH, Kwok-Seng L,
et al. Overexpression of cyclooxygenase-2 in nasopharyngeal
carcinoma and association with epidermal growth factor
receptor expression. Arch Otolaryngol Head Neck Surg 2005;
131: 147_52.
22 Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee
JD, et al. Synchronous co-expression of epidermal growth factor
receptor and cyclooxygenase-2 in carcinomas of the uterine
cervix: a potential predictor of poor survival. Clin Cancer Res
2004; 10: 1366_74.
23 Richardson CM, Richardson D, Swinson DE, Swain WA, Cox
G, O'Byrne KJ. Cyclooxygenase-2 protein levels are
independent of epidermal growth factor receptor expression
or activation in operable non-small cell lung cancer. Lung
Cancer 2005; 48: 47_57.
24 Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction
between epidermal growth factor receptor and cyclooxygenase
2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther
2005; 4:1448_55.
25 Zhang X, Neufeld AH. Signal transduction pathways for
epidermal growth factor stimulated cyclooxygenase-2
induction in astrocytes. Exp Eye Res 2007; 85: 280_8.
|